A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of oral COH29, a novel ribonucleotide reductase (RNR) inhibitor in adult patients (pts) with advanced solid tumors
Chao, Joseph, Synold, Timothy W., Frankel, Paul Henry, Mortimer, Joanne E., Chung, Vincent M., Smith, D. Lynne, Nallu, Rajiv, Pillai, Raju K., Simpson, James, Horne, David, Kwak, Larry W., Malkas, Linda
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article